Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Helix BioPharma, a biopharmaceutical company that develops products for the prevention and treatment of cancer based on its proprietary technologies, has reported a revenue of $4.43m for the fiscal 2010, an increase of 15.4%, compared to $3.84m for the year 2009.
Subscribe to our email newsletter
Helix BioPharma said that the product revenue contributed to the increase in revenue in fiscal 2010 when compared to fiscal 2009 and was offset slightly by a decrease in license fees and royalties.
Product revenue in fiscal 2010 totaled $3.92m and represents an increase of 21% when compared to product revenue in fiscal 2009 of $3.24m.
Helix BioPharma posted a net loss of $14.47m, or $0.24 loss per diluted share for the full year ended 2010, compared to $14.1m, or $0.27 loss per diluted share, for the year 2009.